Undecylenic Acid Veterinary Grade API is the undec-10-enoic acid entity identified by CAS 112-38-9, EINECS 203-965-8, and molecular formula C₁₁H₂₀O₂; the theoretical molecular mass is 184.28 g/mol. The grade designation is Undecylenic Acid Veterinary Grade API, with the CAS registry number serving as the unambiguous chemical model identifier rather than a proprietary product code. The substance is a linear C11 unsaturated fatty acid with a terminal vinyl group and a carboxylic acid function. Because its solidification range lies at approximately 22–24 °C, the material may present as a white to faint yellow low-melting solid in temperature-controlled warehousing or as a pale oily liquid in warm ambient conditions. This thermal behavior is the primary handling variable that distinguishes it from higher-melting fatty acid powders and from zinc undecylenate. The veterinary API grade is not the technical pyrolysis fraction; it is refined, distilled, and compendially controlled for use as a drug substance in tablets, capsules, injections, oral powders, granules, feed premixes, and topical or otic solutions. Pharmacopoeial impurity control, residual solvent compliance, and elemental impurity documentation are specified because the same API may be used across multiple animal dosage forms, including parenteral preparations where bacterial endotoxin and particulate controls become release-limiting.

What Monograph, Residual Solvent, and Elemental Impurity Controls Are Applied to This Veterinary API?

The release panel follows current USP/NF and Ph. Eur. monographs for undecylenic acid, with additional veterinary-dossier requirements under VICH GL18 for residual solvents and VICH GL11 for impurities. Assay by gas chromatography after esterification controls total undecylenic acid content on an anhydrous basis; the unsaturation is quantified by iodine value, while carboxyl integrity is quantified by acid value and saponification value. Because industrial production commonly starts from castor oil-derived ricinoleate pyrolysis, homologous saturated and unsaturated fatty acids are the most relevant organic impurities and are controlled by the monograph related-substances test. Residual solvent testing is aligned to USP <467>, with typical monitoring for methanol, ethanol, toluene, and pyrolysis-derived low-molecular-weight hydrocarbons. Elemental impurities are controlled in accordance with USP <232>/<233> and the VICH guideline; for feed premix applications, regional heavy-metal limits may also apply. Microbial enumeration follows USP <61>/<62>, and bacterial endotoxin testing per USP <85> is available for parenteral-grade material.

Compression and encapsulation of undecylenic acid are constrained by the solid–liquid transition at ordinary cleanroom temperatures. In direct compression trials, tablet formulations containing 15–25% w/w undecylenic acid have required chilled granulation feed at ≤20 °C and polished stainless steel tooling to reduce sticking; if turret temperatures exceed 24 °C, the drug substance can undergo plastic flow and form blade smears on the press. Wet granulation is more practical when the API is first adsorbed onto microcrystalline cellulose or colloidal silicon dioxide at 0.5–2.0% w/w; aqueous binder systems are avoided because the free acid is practically insoluble and can phase-separate during drying. Vacuum drying at product temperatures not exceeding 25 °C and pressures below 20 kPa absolute preserves particle integrity. Capsule filling of neat powder is not recommended above 40% RH; powder hoppers should be cooled to 15–18 °C.

For feed premixes and oral powders, the low melting point reduces the energy input required for mixing but increases the risk of smearing in high-shear mixers. Production-scale ribbon blenders and plow mixers are typically jacketed at 10–15 °C, and hydrophobic fumed silica or precipitated silica is added as a partitioning agent. The API can be sprayed as a warm liquid onto calcium carbonate or corn cob carriers; after solidification, the granules are sieved through a 1.0 mm screen. Batch-to-batch assay variability in this operation is governed more by carrier temperature than by blend time once the material exceeds 20 °C, because partial melting creates low-melting agglomerates that resist subsequent dry screening.

Parenteral Vehicle Selection, Filtration, and Stability Boundaries

For injectable formulations, the free acid is dissolved in nonaqueous vehicles such as medium-chain triglycerides, propylene glycol, or benzyl alcohol-containing systems; aqueous dilution causes precipitation, so the injection vehicle must remain nonaqueous or be emulsified. Terminal filtration of low-viscosity nonaqueous solutions through 0.2 µm membranes is compatible when the low-melting fatty acid is fully dissolved; however, filter validation must account for viscosity changes at storage temperatures below 25 °C. If the solution is cooled toward the solidification range, drug precipitation on the filter medium increases pressure drop and reduces filtration capacity. Bacterial endotoxin control becomes release-limiting because the API is not inherently sterile; dry heat or steam sterilization of the neat drug substance is generally unsuitable due to the terminal vinyl group and low melting point. Aseptic filtration of the formulated nonaqueous solution, preceded by bioburden reduction and validated filter integrity testing, is the standard parenteral processing route. Published data for heat sterilization of undecylenic acid in aqueous parenteral vehicles is limited; therefore, aseptic filtration rather than terminal steam sterilization is preferred.

When Low-Melting Solid Handling Is Compared Across Milling, Drying, and Feed-Premix Blending

Mechanical milling of undecylenic acid at ambient temperature is limited by frictional heating. On a laboratory cone mill with 0.5 mm screen, product temperature can rise by 3–6 °C within 10 min of continuous operation; this is sufficient to cross the solidification range. Therefore, production milling is performed with jacketed mills at 5–10 °C, and throughput is reduced relative to higher-melting fatty acid powders. The milled product is discharged directly into double polyethylene-lined vessels that are sealed under nitrogen. Drying in tray ovens is generally unsuitable unless the oven is equipped with circulating air at dew point ≤4 °C and product temperature control below 25 °C. Fluid-bed drying with inlet air at 18–22 °C and low humidity is used for granules, but the bed must be monitored for defluidization caused by partial melting. In feed-premix blending, frictional heat from high-speed plows can create localized hot spots above 24 °C; this failure mode is controlled by using jacketed mixers, interrupted mixing cycles, and offline temperature checks.

The product differs from zinc undecylenate and from technical-grade undecylenic acid in release controls and handling behavior. The free acid is an oily/low-melting solid with high acid value and pH-dependent antifungal activity; its zinc salt is a higher-melting solid with reduced acidity and different dissolution kinetics. The veterinary API is not interchangeable with technical pyrolysis acid because technical material contains homologous fatty acids, color bodies, and residual pyrolysis reaction products that are not controlled for drug substance use.

Pharmacologically, undecylenic acid differs from azole antifungals because it does not inhibit lanosterol 14α-demethylase. Its activity is associated with the undissociated acid form and is pH-dependent; maximum activity is observed when formulation pH remains below the pKa of approximately 4.8. This pH constraint is less critical for zinc undecylenate, which can be formulated as a suspension and slowly releases the active acid at the cutaneous surface. The veterinary API should not be dry-blended with alkali metal stearates, amines, or strongly basic buffers because salt formation reduces the undissociated acid fraction and creates smearing or gelling during granulation. Oxidizing agents and transition metal ions such as copper and iron should also be avoided due to the terminal vinyl group.

Stability Program, Packaging, and Storage Boundaries for Multi-Dosage-Form Intermediates

Long-term stability of the neat API is limited by oxidative degradation at the terminal double bond and by temperature cycling around the solidification point. Sealed containers with nitrogen headspace and polyethylene liners are used to exclude atmospheric oxygen. Storage is specified at 15–25 °C, protected from light and moisture. Under these conditions, the API is typically retested rather than assigned a fixed expiry; compendial stability requirements follow VICH GL3 for new veterinary drug substances and VICH GL5 for photostability. Open-container hold times in production should be minimized at relative humidity above 60% RH, because the low-melting solid can exhibit surface wetting and increased moisture pickup in humid air. For injectable-grade material, end-user handling requires controlled-nitrogen blanketing and sterile filtration validation; opened containers should not be returned to the warehouse. Published terminal oxidation rate constants for this exact veterinary-grade material are limited; therefore, oxidative stability should be confirmed by forced degradation studies in the final formulation.

For premix and low-dose oral powder applications, milled material with controlled particle-size distribution is released to maintain blend uniformity and reduce segregation during transport. Typical release criteria include not more than 10% w/w retained on a 0.5 mm sieve and not less than 90% w/w passing through a 1.0 mm sieve. Homogeneity testing in finished feed premixes uses top, middle, and bottom sampling from production-scale ribbon blenders; acceptance limits are established in the marketing authorization rather than in the API monograph. Because undecylenic acid is a low-melting solid, the primary batch failure mode at commercial scale is not chemical degradation but agglomeration after partial melting, which produces low-assay stratification and poor dose uniformity. Control therefore centers on maintaining product contact surfaces below 20 °C, limiting dwell time in high-shear mixers, and protecting the milled API from humidity during transfer.